If you have been reading about Melanotan II and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
He worked on other methods of analytical separation of biological materials, notably electrophoresis and displacement chromatography, but also was influential in developing biochemical engineering within the Chemical Engineering Department at Yale. He published about 300 papers and held 9 patents. He was a member of the United States National Academy of Engineering. He received many other honors and awards and is remembered in the Horváth Laboratory of Separation Science at Innsbruck.
The conformational mobility of serpins provides a key advantage over static lock-and-key protease inhibitors. In particular, the function of inhibitory serpins can be regulated by allosteric interactions with specific cofactors. The X-ray crystal structures of antithrombin, heparin cofactor II, MENT and murine antichymotrypsin reveal that these serpins adopt a conformation wherein the first two amino acids of the RCL are inserted into the top of the A β-sheet. The partially inserted conformation is important because co-factors are able to conformationally switch certain partially inserted serpins into a fully expelled form. This conformational rearrangement makes the serpin a more effective inhibitor. The archetypal example of this situation is antithrombin, which circulates in plasma in a partially inserted relatively inactive state. The primary specificity determining residue (the P1 arginine) points toward the body of the serpin and is unavailable to the protease. Upon binding a high-affinity pentasaccharide sequence within long-chain heparin, antithrombin undergoes a conformational change, RCL expulsion, and exposure of the P1 arginine. The heparin pentasaccharide-bound form of antithrombin is, thus, a more effective inhibitor of thrombin and factor Xa. Furthermore, both of these coagulation proteases also contain binding sites (called exosites) for heparin. Heparin, therefore, also acts as a template for binding of both protease and serpin, further dramatically accelerating the interaction between the two parties.
== Career == In 1977, Bowman joined International Plasma Corporation of Hayward, California as chief financial officer and general manager of its analytical instrument division. International Plasma Corporation owned Durrum Instrument Corporation, an instrumentation company that had purchased exclusive rights to an emergent technology, Ion chromatography, from Dow Chemical Company. Initial research by Hamish Small and others at the Dow Physical Research Laboratory in Midland, Michigan suggested that inorganic ion analysis would be superior to commonly used wet chemical techniques, but Dow was not interested in pursuing the idea. Bowman became interested in the potential of ion chromatography (IC) while at International Plasma Corporation. In 1980, Smith-Kline acquired International Plasma Corporation. The IC division was spun off as a separate company, under the name Dionex Corporation, in a leveraged buyout (LBO) led by A. Blaine Bowman. Bowman became the president and CEO of the new company, which was incorporated in California in 1980. The company was reincorporated in Delaware in 1986. Dionex began to trade publicly as of 1982. Under Bowman's leadership, Dionex made important advances both scientifically and economically. The company directed up to nine percent of its revenues back into its ongoing research and development program.
Sources: en.wikipedia.org
== Nanocellulose based water purification system == Nanocellulose based renewable material has a combination of high surface area with high material strength. It is chemically inert and possesses versatile hydrophilic surface chemistry. These properties make them a most promising nanomaterial for usage as a membrane and filter in water purification systems to remove bacterial and chemical contaminants from polluted water. It is noted that nanocellulose material has high potential in water purification technology. Different types of nanocellulose materials available for water purification system includes Cellulose nanocrystals (CNC) and Cellulose nanofibrils (CNF). These are the rod-like nanomaterials whose size ranges from 100 to 2000 nm with the diameter of 2 to 20 nm. Those length and diameter are mostly based on origin and preparation route for the synthesis of nanocellulose. Those nanocellulose materials are used to remove organic pollutants in water such as dyes, oils and pesticides traces present in water. Currently, fully biobased membrane using nanocellulose are fabricated which is used to remove metal ions such as Cu2+, Fe2+ etc, sulfates, fluorides and other organic compounds. This bio-based nanocellulose filter has more advantage to conventional filters. Nanocellulose is prepared by various methods such as sulphuric acid hydrolysis and mechanical grinding method. Water purification system is mainly based on the principle of absorption.
To predict if the production of mendelevium would be possible, the team made use of a rough calculation. The number of atoms that would be produced would be approximately equal to the product of the number of atoms of target material, the target's cross section, the ion beam intensity, and the time of bombardment; this last factor was related to the half-life of the product when bombarding for a time on the order of its half-life. This gave one atom per experiment. Thus under optimum conditions, the preparation of only one atom of element 101 per experiment could be expected. This calculation demonstrated that it was feasible to go ahead with the experiment. The target material, 253Es, could be produced readily from irradiating plutonium: one year of irradiation would give a billion atoms, and its three-week half-life meant that the element 101 experiments could be conducted in one week after the produced einsteinium was separated and purified to make the target. However, it was necessary to upgrade the cyclotron to obtain the needed intensity of 1014 alpha particles per second; Seaborg applied for the necessary funds.
Chief Executive Officer, Key Assets Europe. For services to Fostering. Rowan Edwin Crozier. Chief Executive Officer, C Brandauer & Co. For services to Manufacturing and Enterprise. Dr. Donald Murray Cruickshank. General Practitioner, Upper Deeside. For services to the Medical Profession and to the community of Braemar, Aberdeenshire. Diana Jane Andrews Cunningham. Peer Trainer, Sussex Recovery College. For services to Mental Health. Suzette Louise Davenport, QPM. Chair, National Driver Offending Retraining Scheme. For services to Road Safety. Jessica Miriam Bryson Davidson. Senior Clinical Forensic Charge Nurse. For services to Forensic Nursing and to Victim Support in Scotland. Donna Marie Dawber. News and Campaigns Manager, Merseyside Police. For services to Law and Order. Dr. Edward James Day. Clinical Reader in Addiction Psychiatry, University of Birmingham. For services to Vulnerable People. Shaun Andrew Day. Headteacher, The Unicorn School, Abingdon, Oxfordshire. For services to Education. Paula Rosemary Deas. Deputy Chief Executive, Coventry and Warwickshire Local Enterprise Partnership. For services to the community in the West Midlands. Keith Deller. For charitable services to the community in Suffolk. Jack Robert Clarke Deverson. Co-Founder and Managing Director, Evidence Based Education. For services to Education. Ruth Heather Devine. Route Panel Member, Institute for Apprenticeships and Technical Education. For services to Further Education and Apprenticeships. Deborah Heather Dixon (Deborah Williams). For services to the community in Poole, Dorset.
Sources: en.wikipedia.org
Sandra Kazahn Masur is an American cell biologist and activist for women in academia. Masur is a professor of Ophthalmology as well as Pharmacological Sciences at Icahn School of Medicine at Mount Sinai (ISMMS) in New York City. Her research focused on membrane transport and wound healing. As a leader in promoting gender equity in science, technology, engineering, mathematics, and medicine (STEMM), Masur is the founding Director of the Office for Women's Careers at ISMMS, the Chair of the Committee on Special Awards, and Title IX Coordinator. In recognition of her commitment to developing programs that mentor all scientists, the American Society for Cell Biology named the Senior Leadership Award of the Women in Cell Biology, the Sandra K. Masur Award in her honor.
== Locations == The company opened its first location on August 26, 2002, near the intersection of 21st Street and Tyler Road in Wichita; this location is still in operation. In November 2022, it was announced that Freddy's would be expanding to nine provinces in Canada, with the first location set for a 2025 opening. As of September 10, 2025, Freddy's had 560 locations across 37 states. Additionally, the chain opened in non-traditional locations such as OKC Will Rogers International Airport in Oklahoma City and Busch Stadium in St. Louis.
=== Immunology and neurobiology === Hood also made generative discoveries in the field of molecular immunology. His studies of the amino acid sequences of immunoglobulins (also known as antibodies) helped to fuel the 1970s' debate regarding the generation of immune diversity and supported the hypothesis advanced by William J. Dreyer that immunoglobulin (antibody) chains are encoded by two separate genes (a constant and a variable gene). He (and others) conducted pioneering studies on the structure and diversity of the antibody genes. This research led to verification of the "two genes, one polypeptide" hypothesis and insights into the mechanisms responsible for the diversification of the immunoglobulin variable genes. Hood shared the Lasker Award in 1987 for these studies. Additionally, Hood was among the first to study, at the gene level, the MHC (major histocompatibility complex) gene family and the T-cell receptor gene families as well as being among first to demonstrate that alternative RNA splicing was a fundamental mechanism for generating alternative forms of antibodies. He showed that RNA splicing is the mechanism for generating the membrane bound and the secreted forms of antibodies. In neurobiology, Hood and his colleagues were the first to clone and study the myelin basic protein (MBP) gene. The MBP is a central component in the sheath that wraps and protects neurons. Hood demonstrated that the condition called "shiverer mouse" arose from a defect in the MBP gene.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.